Related Experiment Video
Updated: Jul 13, 2026
11:17
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy
Sami Anttila1, Kaija Huuhka, Martti Huuhka
1University of Tampere Medical School, University of Tampere, Tampere, Finland. samia@koti.soon.fi
The Pharmacogenomics Journal
|August 19, 2007
Summary
The catechol-O-methyltransferase (COMT) high/high genotype was linked to better electroconvulsive therapy (ECT) response in patients with treatment-resistant depression. This suggests COMT genotype influences ECT effectiveness for depression.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Catechol-O-methyltransferase (COMT) enzyme activity influences dopaminergic neurotransmission.
- COMT genetic variations are implicated in various neurological and psychiatric conditions.
- Previous research suggests a potential link between COMT and depression treatment outcomes.
Purpose of the Study:
- To investigate the association between COMT genotypes and electroconvulsive therapy (ECT) response in patients with treatment-refractory depression.
- To determine if specific COMT genotypes predict ECT efficacy.
Main Methods:
- A cohort of 119 patients with treatment-refractory depression undergoing ECT was studied.
- COMT genotypes were analyzed.
- Treatment response to ECT was assessed.
Main Results:
- Patients with the COMT high/high genotype showed a significantly higher frequency of response to ECT.
- The high/high genotype is associated with increased COMT enzyme activity and reduced prefrontal cortex dopaminergic activity.
Conclusions:
- The COMT high/high genotype may serve as a predictive biomarker for ECT response in treatment-resistant depression.
- COMT genetic variations play a role in modulating treatment outcomes for severe depression.
- Further research is warranted to elucidate the precise mechanisms underlying this association.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...